MCL1 and neuroblastoma: We verified that MLN8237 and VX680 treatment each resulted in loss of p4E-BP1 and MCL-1 in MYCN-amplified neuroblastoma cells (Figure S5B), as did knockdown of Aurora A (Figure S5C).